3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
4
Plasma cell
2
Myeloid
2
Lymphoid
2
Gastrointestinal
2
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Dermatologic
1
Classical hematology
1
CNS
1
Breast
1
Conditions
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Ovarian Neoplasms
2
Melanoma
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Laryngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Erdheim-Chester Disease
1
Cholangiocarcinoma
1
Adenocarcinoma, Follicular
1
Interventions
trametinib
2
pertuzumab
2
dabrafenib
2
Trastuzumab
2
Magnetic Resonance Spectroscopy
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
sapanisertib
1
romidepsin
1
relatlimab
1
palbociclib
1
osimertinib
1
omipalisib
1
margetuximab
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
defactinib
1
copanlisib
1
cobimetinib
1
cc-486
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Vemurafenib
1
Sunitinib
1
Specimen Handling
1
Palliative Care
1
PF-05280014
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
cobimetinib
×
Head & Neck
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled